Maxim Group analyst Jason McCarthy has maintained their bullish stance on UNCY stock, giving a Buy rating today.
Jason McCarthy has given his Buy rating due to a combination of factors including Unicycive Therapeutics’ upcoming key event, the PDUFA date for oxylanthanum carbonate (OLC) on June 28, 2025. The bioequivalence data and the results from the FDA requested safety/tolerability study in patients with chronic kidney disease suggest a favorable risk/reward scenario. Additionally, the TDAPA opportunity further enhances the potential upside.
Despite the challenging microcap biotech markets in 2025, UNCY shares have rebounded approximately 45% in the last six months. The strategic efforts by Unicycive to build awareness through presentations at major medical conferences are expected to generate enthusiasm and potentially increase the stock’s value as the PDUFA date approaches. Consequently, McCarthy has lowered the revenue risk adjustment, raising the 12-month price target to $3.00.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Medicus Pharma Ltd. According to TipRanks, McCarthy has an average return of -22.3% and a 23.99% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $7.50 price target.